Barinder Kang, PhD

Vice President & Head, US Oncology Medical, Radioligand Therapies
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Poster(s):

• (327) Healthcare resource utilization (HCRU) and costs among chemotherapy-naïve patients with metastatic castration‑resistant prostate cancer (mCRPC): a real-world assessment using data from the Veterans Affairs Healthcare System (VAHCS)
  Wednesday, October 29, 2025